دورية أكاديمية
Neuroleptic Malignant Syndrome in Patients With Dementia: Experiences of A Single Memory Clinic.
| العنوان: | Neuroleptic Malignant Syndrome in Patients With Dementia: Experiences of A Single Memory Clinic. |
|---|---|
| المؤلفون: | Isik AT; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir., Kaya D; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir., Ontan MS; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir., Mutlay F; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir., Bulut EA; Department of Geriatric Medicine, Adana City Research and Training Hospital, Adana., Dost FS; Department of Geriatric Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir., Erken N; Department of Geriatric Medicine, University of Gazi Antep, Gaziantep., Aydin AE; Department of Geriatric Medicine, Sivas Numune Hospital, Sivas, Turkey. |
| المصدر: | Clinical neuropharmacology [Clin Neuropharmacol] 2023 Nov-Dec 01; Vol. 46 (6), pp. 209-213. Date of Electronic Publication: 2023 Sep 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7607910 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-162X (Electronic) Linking ISSN: 03625664 NLM ISO Abbreviation: Clin Neuropharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: New York, Raven Press. |
| مواضيع طبية MeSH: | Neuroleptic Malignant Syndrome*/diagnosis , Neuroleptic Malignant Syndrome*/etiology , Neuroleptic Malignant Syndrome*/drug therapy , Antipsychotic Agents*/adverse effects , Neurodegenerative Diseases*/complications , Dementia*/complications , Dementia*/drug therapy, Humans ; Female ; Aged ; Male ; Dihydroxyphenylalanine/therapeutic use |
| مستخلص: | Objectives: Neuroleptic malignant syndrome (NMS) is a life-threatening condition that occurs as an adverse reaction to antipsychotic and antiemetic agents or sudden withdrawal of dopaminergic medications. Given the metabolic and functional reserves and the comorbidities in older adults, NMS may show an atypical course. Methods: The medical records of patients with neurodegenerative diseases leading to dementia between 2013 and 2020 were reviewed for the diagnosis of NMS. Demographic and clinical characteristics of the patients were obtained from the records of laboratory parameters, management, and length of stay. Results: Fifteen older adults (19 episodes) diagnosed with NMS were included. The median age was 76 years, and 5 were female. Ten of 15 NMS patients were atypical. Most of them had an infection accompanying NMS. Neuroleptic malignant syndrome was caused by antidopaminergic agents (5 antipsychotics, 1 metoclopramide) in 6 episodes and discontinuation of a dopaminergic agent, l -DOPA, in 12 episodes. In 1 patient, it was associated with simultaneous use of domperidone and amantadine withdrawal. Rigidity in NMS due to l -DOPA discontinuation was higher than in those due to antipsychotic use ( P = 0.027). Two of our patients needed intensive care, and 1 died. Conclusions: This study highlights the high frequency of atypical NMS and the importance of early recognition of this potentially fatal syndrome, which can accompany neurodegenerative diseases and infections in older adults. Competing Interests: Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Simon LV, Hashmi MF, Callahan AL. Neuroleptic Malignant Syndrome . In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol 2015;13(3):395–406. Delay J, Pichot P, Lemperiere T, et al. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses [in French]. Ann Med Psychol (Paris) 1960;118(1):145–152. Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011;72(9):1222–1228. Modi S, Dharaiya D, Schultz L, et al. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care 2016;24(1):97–103. Kocyigit SE, Soysal P, Isik AT. Neuroleptic malignant syndrome associated with only one dose of metoclopramide in an older adult. Geriatr Gerontol Int 2017;17(8):1232–1233. Argyriou AA, Drakoulogona O, Karanasios P, et al. Lithium-induced fatal neuroleptic malignant syndrome in a patient not being concomitantly treated with commonly offending agents. J Pain Symptom Manage 2012;44(6):e4–e6. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 1990;28(6):518–521. Kaufman DM, Geyer HL, Milstein MJ, eds. Chapter 6: muscle disorder. In: Kaufman's Clinical Neurology for Psychiatrists . 8th ed. Philadelphia, PA: Elsevier; 2017:81–102. Caroff SN, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in elderly patients. Expert Rev Neurother 2007;7(4):423–431. Canaslan K, Ates Bulut E, Kocyigit SE, et al. Predictivity of the comorbidity indices for geriatric syndromes. BMC Geriatr 2022;22(1):440. Arora A. Parkinsonism hyperpyrexia syndrome caused by abrupt withdrawal of ropinirole. Br J Hosp Med 2013;74:12–17. Thomas A, Onofrj M. Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. Mov Disord 2005;20(12):1671. Kahl A, du Bois A, Harter P, et al. Prognostic value of the age-adjusted Charlson Comorbidity Index (ACCI) on short- and long-term outcome in patients with advanced primary epithelial ovarian cancer. Ann Surg Oncol 2017;24(12):3692–3699. Isik AT, Danyeli AE, Kaya D, et al. The importance of brain banking for dementia practice: the first experience of Turkey. Cell Tissue Bank 2020;21(3):367–375. Unutmaz GD, Soysal P, Tuven B, et al. Costs of medication in older patients: before and after comprehensive geriatric assessment. Clin Interv Aging 2018;13:607–613. Ates Bulut E, Soysal P, Isik AT. Frequency and coincidence of geriatric syndromes according to age groups: single-center experience in Turkey between 2013 and 2017. Clin Interv Aging 2018;13:1899–1905. Isik AT, Erken N, Yavuz I, et al. Orthostatic hypotension in patients with Alzheimer's disease: a meta-analysis of prospective studies. Neurol Sci 2022;43(2):999–1006. Dost FS, Ates Bulut E, Dokuzlar O, et al. Sarcopenia is as common in older patients with dementia with Lewy bodies as it is in those with Alzheimer's disease. Geriatr Gerontol Int 2022;22(5):418–424. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005;66(5):633–637. Ballard C, Grace J, McKeith I, et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998;351(9108):1032–1033. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009;10(1):136–140. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23(6):477–492. Singhai K, Kuppili PP, Nebhinani N. Atypical neuroleptic malignant syndrome: a systematic review of case reports. Gen Hosp Psychiatry 2019;60:12–19. Sarkar S, Gupta N. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association. BJPsych Bull 2017;41(4):211–216. Isik AT. COVID-19 infection in older adults: a geriatrician's perspective. Clin Interv Aging 2020;15:1067–1069. Gurrera RJ, Mortillaro G, Velamoor V, et al. A validation study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant Syndrome. J Clin Psychopharmacol 2017;37(1):67–71. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand 2005;112(3):238–240; discussion 240. Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology 2005;64(7):1162–1169. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85(1):129–135. Strawn JR, Keck PE Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164(6):870–876. |
| المشرفين على المادة: | 0 (Antipsychotic Agents) 63-84-3 (Dihydroxyphenylalanine) |
| تواريخ الأحداث: | Date Created: 20231114 Date Completed: 20231115 Latest Revision: 20231206 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1097/WNF.0000000000000570 |
| PMID: | 37962307 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!